PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
-0.23
Both firms show negative OCF/share. Martin Whitman would suspect an industry-wide challenge or high growth burn rates.
-0.23
Both firms show negative FCF/share. Martin Whitman might see an industry-wide capital intensity challenge.
No Data
No Data available this quarter, please select a different quarter.
0.63
0.5–0.75x TRAW's 1.13. Martin Whitman would worry net income is running ahead of actual cash.
-21965.22%
Both show negative ratio. Martin Whitman would question if the industry struggles with unprofitable or upfront costs.